, Singapore

Daily Markets Briefing: STI down 0.94%

Wall Street gains could uplift the local bourse today.

The Straits Times Index (STI) ended 30.44 or 0.38% lower at 3,213.92.

The FTSE ST Mid Cap Index fell 1.91%, whilst the FTSE ST Small Cap Index slipped -1.35%.

The top active stocks were DBS, which dipped 1.27%, Singtel, which fell 0.92%, OCBC Bank, which slid 1.05%, UOB, which grew 0.04%, and Keppel, with a 1.21% fall.

According to OCBC Investment Research, US stocks finished mostly higher, with the major benchmarks posting strong weekly gains and a strong finish in August.

Six out of eleven S&P 500 industries ended higher, led by Real Estate (0.42%) and Consumer Discretionary (0.37%) whilst Energy (-0.73%) and Utilities (-0.45%) led the declines. The index advanced 3.03% for the month.

"We expect the STI to attempt to claw higher today amidst the modest gains on Wall Street Friday," OCBC Investment Research noted."

Join Singapore Business Review community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Top News

DBS and OCBC expected to deliver steady Q1 net profits
Their net interest margins will ease as a result of their Hong Kong loans.
Singapore's maritime cluster navigates towards digital, green future
Adapting to emerging challenges, such as the adoption of alternative fuels, is deemed crucial for the country's maritime sector.
Shipping & Marine
SCG and A*STAR unveil joint labs for cellular immunotherapy enhancement
The partnership has a funding of nearly $30m supported under Singapore's Research, Innovation and Enterprise 2025 plan.
Healthcare